20-F: Smith & Nephew Reports Strong Financial Performance in 2024, Driven by 12-Point Plan

Smith & Nephew's 2024 annual report highlights significant progress in operational and financial performance, driven by the company's 12-Point Plan, with revenue growth, improved profitability, and strong cash flow generation.

Summary

• Smith & Nephew's 2024 results show a positive turnaround, with revenue increasing to $5,810 million, a 4.7% reported growth and 5.3% underlying growth.
• Operating profit rose significantly to $657 million, reflecting a 54.6% increase.
• The trading profit margin improved by 60bps to 18.1%, resulting in a trading profit of $1,049 million, up 8.2%.
• Cash generated from operations increased substantially to $1,245 million, a 50.2% increase.
• Adjusted Return on Invested Capital (ROIC) also saw a significant improvement, rising 150bps to 7.4%.
• The company's 12-Point Plan has been instrumental in driving these improvements, with most actions completed by the end of 2024.
• For 2025, Smith & Nephew is guiding to underlying revenue growth of around 5% and a trading profit margin of 19% to 20%.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and clear progress on strategic initiatives. While acknowledging challenges, the overall tone is optimistic and confident in future performance.

Positives

• Sustained revenue growth above historical levels.
• Significant improvement in cash flow generation.
• Successful cost savings from optimizing the manufacturing network.
• Strong innovation pipeline with new product launches.
• Improved employee engagement and recognition with the Gallup Exceptional Workplace Award.

Negatives

• Headwinds from input cost inflation and merit increases, China VBP pricing, and transactional foreign exchange impacted trading profit margin.
• Underperformance in US Orthopaedics business and pressures of Volume Based Procurement (VBP) programmes in China.
• Inventory levels were higher than originally expected, requiring continued focus on improvement.

Risks

• The company faces risks related to global markets, including demographic shifts, healthcare budget constraints, and technological advancements.
• There are risks associated with cost of healthcare, including government price sensitivity and domestic production policies.
• The company operates in a highly regulated environment, creating barriers to entry for new market participants.
• The company is exposed to seasonality, with higher procedure volumes during winter months.
• The company faces risks related to cybersecurity, supply chain disruptions, and geopolitical uncertainty.

Future Outlook

For 2025, Smith & Nephew is targeting underlying revenue growth of around 5% and a trading profit margin of 19% to 20%.

Management Comments

• Deepak Nath stated that Smith+Nephew's transformation remains on track, with the 12-Point Plan increasingly delivering better financial performance.
• Deepak Nath mentioned that the company has made solid progress fixing the foundations and expects a step-up in returns in 2025, including significant margin expansion.
• John Rogers expressed his belief that free cash flow is a key indicator of an organization's fundamental health and was pleased with the progress made in 2024.
• John Rogers stated that the company is pleased that the operational and commercial actions, combined with the sustained high cadence of innovation, are producing consistently higher growth than in the past.

Industry Context

The medical technology sector is supported by strong long-term growth drivers, including demographic shifts, technological advancements, and the increasing decentralization of care.

Comparison to Industry Standards

• Smith+Nephew operates in global markets valued at approximately $50 billion annually.
• The company holds leading positions in growing markets, including Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
• Smith+Nephew competes with major players in the industry, such as Stryker, Zimmer Biomet, DePuy Synthes, and Arthrex.
• The company's performance is assessed against industry-standard levels of margin and return.

Management Changes

Legal Proceedings

• The company is involved in various legal proceedings, including product liability claims related to metal-on-metal hip implants.

Stakeholder Impact

• The company's performance directly impacts shareholders through dividend payments and share value.
• Employees are affected by the company's culture, compensation, and development opportunities.
• Customers benefit from the company's innovative products and services.
• The company's operations have an impact on the environment and local communities.
• The company's relationships with suppliers are crucial for maintaining a resilient supply chain.

Next Steps

• The company will continue to focus on driving further improvement in ROIC.
• The company will continue to prioritize investment in areas where it expects to see the highest incremental ROIC.
• The company will continue to focus on driving productivity and asset efficiency to their full potential.
• The company will continue to work to make its culture ever stronger, building on its three pillars of Care, Collaboration and Courage.

Key Dates